Evaluating the protective effect of a tissue selective estrogen complex (TSEC) in women with newly diagnosed ductal carcinoma in situ

Overview of the Treatment Plan: This is a multicenter randomized, double blind, placebo controlled pre-surgical “Window of opportunity” trial of CE/BZA vs. placebo daily for 28 +/- 7 days in (n=130) postmenopausal women diagnosed with DCIS by core biopsy and undergoing standard of care surgical therapy for DCIS. The interval of time from diagnosis to surgery is on average 4-6 weeks depending on surgical scheduling, type of surgery and the addition of immediate breast reconstruction. Women will be recruited from the Lynn Sage Breast Center and participating sites. Postmenopausal women who meet the eligibility criteria will be randomized to the CE/BZA arm or placebo arm.